Carnegie Investment Counsel Purchases 7,686 Shares of Hologic, Inc. $HOLX

Carnegie Investment Counsel lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 229,214 shares of the medical equipment provider’s stock after buying an additional 7,686 shares during the quarter. Carnegie Investment Counsel owned about 0.10% of Hologic worth $15,470,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Invesco Ltd. increased its holdings in Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. United Services Automobile Association bought a new stake in shares of Hologic in the 1st quarter valued at $347,000. K.J. Harrison & Partners Inc acquired a new position in shares of Hologic during the 2nd quarter valued at $1,987,000. Aberdeen Group plc boosted its stake in Hologic by 2.8% during the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock worth $15,964,000 after acquiring an additional 6,589 shares in the last quarter. Finally, Nordea Investment Management AB grew its holdings in Hologic by 7.2% in the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock worth $168,674,000 after purchasing an additional 174,828 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity

In related news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.88% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HOLX. Stephens cut shares of Hologic from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $78.00 to $76.00 in a research report on Wednesday, October 22nd. Evercore ISI set a $78.00 price objective on Hologic and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Argus increased their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. Five equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, Hologic presently has an average rating of “Hold” and a consensus target price of $79.29.

Hologic Stock Performance

Shares of HOLX stock opened at $74.50 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The firm has a 50-day moving average of $74.45 and a 200-day moving average of $69.12. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.34. The company has a market cap of $16.61 billion, a P/E ratio of 30.04, a P/E/G ratio of 2.11 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.03. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.01 earnings per share. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.